CDT Equity Inc.
CDT evidence brief
What we can confirm
- BioSniper Score:
- 5.0 / 10
- Market Cap:
- $29K
- Lead Asset:
- AZD1656 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for CDT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CDT
CDT Equity Inc. (CDT) is a data-driven pharmaceutical development company that leverages artificial intelligence, solid-form chemistry, and asset repositioning to advance clinical-stage compounds, primarily targeting autoimmune disorders and idiopathic male infertility, while also managing a digital asset treasury.
Key risk: No revenue or approved assets
BioSniper Score
Based on 4 of 6 signals
Market Cap
$29K
Cash Runway
—
Lead Asset
AZD1656 (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates for CDT Equity Inc..
CDT Equity Inc. (CDT) is a data-driven pharmaceutical development company that leverages artificial intelligence, solid-form chemistry, and asset repositioning to advance clinical-stage compounds, primarily targeting autoimmune disorders and idiopathic male infertility, while also managing a digital asset treasury.
- CDT Equity Inc., formerly Conduit Pharmaceuticals Inc., is a data-driven pharmaceutical development and digital asset treasury management company [sec · filed 2026-09-08].
- The company's strategy centers on unlocking the value of deprioritized clinical-stage compounds with Phase I safety data, using co-crystallization and solid-form technologies to extend patent life by up to 20 years [sec · filed 2026-09-08].
- Key pipeline assets include AZD1656 (a glucokinase activator for autoimmune disorders) and AZD5904 (a myeloperoxidase inhibitor for idiopathic male infertility) [sec · filed 2026-09-08].
- As of 2026-06-30, the company reported cash & equivalents of $0.7M, net income of -$4.6M, and shareholders' equity of $103.1M [sec].
- The company has not yet generated significant revenue and expects operating losses and negative cash flow for the foreseeable future, as its clinical assets have not been approved by any regulatory body [sec · filed 2026-09-08].
What works
- The company uses AI-powered disease mapping (via Sarborg Limited) to identify novel therapeutic applications, leveraging a database of over 3,000 disease signatures [sec · filed 2026-09-08].
- Its solid-form chemistry technology can improve drug properties and extend patent life by up to 20 years, potentially creating valuable intellectual property [sec · filed 2026-09-08].
- The pipeline targets multiple therapeutic areas (autoimmune, infertility, oncology, dermatology, animal health), diversifying potential value [sec · filed 2026-09-08].
What to weigh
- The company has no approved clinical assets and has not demonstrated the ability to generate revenue, with significant operating losses expected for the foreseeable future [sec · filed 2026-09-08].
- Cash & equivalents were only $0.7M as of 2026-06-30, which may limit the company's ability to fund ongoing development without additional financing [sec].
- Preclinical drug development is expensive, time-consuming, and uncertain, and key assets like AZD1656 and AZD5904 may fail to demonstrate therapeutic properties in patients [sec · filed 2026-09-08].
- The company's financial condition and operating results may fluctuate significantly due to dependence on developmental milestones and regulatory approvals [sec · filed 2026-09-08].
From the filings
Quoted directly from source documents.
The company's business model focuses on deprioritized clinical-stage compounds with Phase I safety data.
“The Company's strategy is centered on unlocking the untapped value of clinical-stage compounds, particularly those deprioritized by larger pharmaceutical companies with strong, supporting Phase I safety data.”
SEC filings · September 8, 2026
The company has not yet generated revenue and expects continued losses.
“We have not yet demonstrated our ability to generate revenue, and we may never be able to produce revenues or operate on a profitable basis. We expect to experience operating losses and negative cash flow for the foreseeable future.”
SEC filings · September 8, 2026
Key pipeline assets are AZD1656 and AZD5904.
“Our business is dependent on the successful development, regulatory approval, and commercialization of our clinical assets, in particular a glucokinase activator which we believe is active in a range of autoimmune disorders, which we refer to as AZD1656, and a potent, irreversible inhibitor of human Myeloperoxidase that has the potential to treat idiopathic male infertility, which we refer to as AZD5904.”
SEC filings · September 8, 2026
The company changed its name from Conduit Pharmaceuticals Inc. to CDT Equity Inc. in August 2025.
“Effective August 5, 2025, the Company changed its name from Conduit Pharmaceuticals Inc. to CDT Equity Inc.”
SEC filings · September 8, 2026
Risks & what to watch (4)›
Key risks
- No revenue or approved assets — Company has no approved clinical assets and has not generated revenue; expects operating losses and negative cash flow for the foreseeable future [sec · filed 2026-09-08].
- Low cash reserves — Cash & equivalents of only $0.7M as of 2026-06-30 may be insufficient to fund development without additional capital [sec].
- Clinical development uncertainty — Key assets AZD1656 and AZD5904 may fail in preclinical or clinical studies, and the company may never become profitable [sec · filed 2026-09-08].
- Dependence on regulatory milestones — Financial condition may fluctuate significantly due to dependence on FDA approval timelines and developmental milestones [sec · filed 2026-09-08].
What to watch
- Progress of preclinical in-vitro and in-vivo studies for AZD1656 and AZD5904, which are designed to support licensing and commercialization partnerships [sec · filed 2026-09-08].
- Any new patent filings or intellectual property developments, particularly those informed by AI-powered disease mapping from Sarborg [sec · filed 2026-09-08].
- The company's ability to secure additional financing or partnerships given its low cash position of $0.7M as of 2026-06-30 [sec].
- Regulatory updates or announcements regarding the company's clinical assets, as none have been approved by the FDA or any other regulatory body [sec · filed 2026-09-08].
Sources: SEC filings · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run CDT Equity Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CDT Equity Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.23 · 0% dilution
Lead: Preclinical
3 candidates
No upcoming catalysts tracked
0 buys · 4 sells (180d)
Pipeline
Financials
Short Interest
as of May 20, 2026- % of float
- 1.1%
- Days to cover
- 0.2
- Shares short
- 29,314
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CDT short interestGovernance
Frequently asked questions
What is the AI investment thesis for CDT Equity Inc.?
CDT Equity Inc. (CDT) is a data-driven pharmaceutical development company that leverages artificial intelligence, solid-form chemistry, and asset repositioning to advance clinical-stage compounds, primarily targeting autoimmune disorders and idiopathic male infertility, while also managing a digital asset treasury.
What is CDT Equity Inc.'s lead drug candidate?
CDT Equity Inc.'s most advanced tracked candidate is AZD1656 (Preclinical) for Autoimmune disorders.
Who is the CEO of CDT Equity Inc.?
Mr. James Bligh is the chief executive officer of CDT Equity Inc. (CDT).
Where is CDT Equity Inc. headquartered?
CDT Equity Inc. (CDT) is headquartered in Naples, FL, United States.
What therapeutic areas does CDT Equity Inc. focus on?
CDT Equity Inc. develops therapies across Immunology, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.